pharmacokinetics study

BIOLOGICAL2 trials

Sponsors

Assistance Publique - Hôpitaux de Paris

Conditions

Glibenclamide Adverse ReactionJuvenile DermatomyositisPretermTransient; Hypoglycemia, Neonatal

Phase 2

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

CompletedNCT05524311

Assistance Publique - Hôpitaux de ParisJuvenile Dermatomyositis

Start: 2022-11-10End: 2026-01-02Updated: 2026-04-23

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Active, not recruitingNCT05687500

Assistance Publique - Hôpitaux de ParisGlibenclamide Adverse Reaction, Preterm, Transient; Hypoglycemia, Neonatal

Start: 2023-05-20End: 2026-04-30Updated: 2026-04-21